News

Article

Avid Bioservices Expands Mammalian Cell Capacity

Author(s):

Avid Bioservices has launched new CGMP mammalian cell manufacturing suites at its Myford, Calif., facility.

Avid Bioservices, a biologics contract development and manufacturing organization, has completed two expansions within the company’s mammalian cell facilities in Myford, Calif. The company has added two new current good manufacturing practice (CGMP) mammalian cell suites at the site and expects manufacturing in those suites to begin this month, according to an April 4, 2023 company press release.

The CGMP manufacturing suites include both upstream and downstream services. The additional capacity has the potential to generate approximately an additional $100 million in annual revenue, according to the press release.

In addition to launching the new suites at its Myford facility, Avid has also completed its expansion for its mammalian cell process development services, which doubles the company’s total process development capacity. Now operational, this process development expansion is expected to generate an additional $25 million in annual revenue, according to Avid in the release.

Source: Avid Bioservices

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content